CD19 is presently thought to be the best accessible target for CAR-T cell treatment in blood cancer [63], whereas autophagic degradation of GZMB represents a novel method for hypoxic tumor cells to avoid natural killer cell-mediated lysis, and IFNG is important in maintaining immune homeostasis [64, 65]. The gene discussed is CD19; the disease is neoplasm.